Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV-B in chronic hepatitis B
NCT04843852Phase 1Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Hepatitis B vaccine in Chronic Hepatitis B (CHB), sponsored by University of Maryland, Baltimore. Primary endpoints: Safety and reactogenicity of HEPLISAV-B, Occurrence of unsolicited adverse events and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
Hepatitis B vaccine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04843852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843852.